| advanced breast cancer (metastatic) | All results are NS for efficacy inferior to megestrol acetate in terms of Clinical benefit (assessable) in Mourisden, 2001 inferior to megestrol acetate in terms of Objective response (assessable) in Mourisden, 2001 inferior to megestrol acetate in terms of diarrhoea in Mourisden, 2001 inferior to megestrol acetate in terms of Objective response (randomised) in Mourisden, 2001 inferior to megestrol acetate in terms of Clinical benefit (randomised) in Mourisden, 2001 inferior to megestrol acetate in terms of Objective response (assessable) in Rose, 2003 inferior to megestrol acetate in terms of Objective response (randomised) in Rose, 2003 inferior to megestrol acetate in terms of Objective response (assessable) in Tominaga, 2003 inferior to megestrol acetate in terms of Objective response (randomised) in Tominaga, 2003 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Buzdar, 2001 | vs megestrol acetate | vaginal bleeding 0.08 [0.01; 0.64] | | Clinical benefit (assessable) 0.90 [0.64; 1.25] Objective response (assessable) 0.95 [0.60; 1.49] diarrhoea 1.01 [0.30; 3.44] overall survival (reported or calculated) 0.92 [0.47; 1.82] nausea 1.12 [0.62; 2.01] progression-free survival (reported or calculated) 0.99 [0.51; 1.91] Objective response (randomised) 1.04 [0.66; 1.63] Clinical benefit (randomised) 0.88 [0.62; 1.23] hot flushes 0.97 [0.57; 1.64] | | Dombernowsky, 1998 | vs megestrol acetate | | | Clinical benefit (assessable) 0.92 [0.69; 1.22] Objective response (assessable) 0.70 [0.46; 1.05] vomiting 1.41 [0.64; 3.14] diarrhoea 2.39 [0.85; 6.74] overall survival (reported or calculated) 0.82 [0.40; 1.70] nausea 1.21 [0.65; 2.26] progression-free survival (reported or calculated) 0.98 [0.49; 1.95] Objective response (randomised) 0.70 [0.46; 1.06] Clinical benefit (randomised) 0.92 [0.69; 1.23] arthralgia 1.67 [0.90; 3.09] rash 1.81 [0.67; 4.88] hot flushes 1.55 [0.60; 3.99] | | Mourisden, 2001 | vs megestrol acetate | | Clinical benefit (assessable) 0.78 [0.67; 0.90] Objective response (assessable) 0.67 [0.53; 0.84] diarrhoea 9.00 [1.14; 70.75] Objective response (randomised) 0.67 [0.53; 0.84] Clinical benefit (randomised) 0.78 [0.67; 0.91] | nausea 1.01 [0.76; 1.35] progression-free survival (reported or calculated) 0.70 [0.40; 1.22] arthralgia 1.06 [0.78; 1.44] hot flushes 1.14 [0.85; 1.51] | | Gershanovich, 1998 | vs megestrol acetate | | | overall survival (reported) 0.64 [0.31; 1.33] Clinical benefit (assessable) 0.83 [0.62; 1.11] Objective response (assessable) 0.65 [0.40; 1.06] progression-free survival (reported or calculated) 0.72 [0.36; 1.43] Objective response (randomised) 0.64 [0.39; 1.04] Clinical benefit (randomised) 0.81 [0.60; 1.09] | | Goss, 2007 | vs megestrol acetate | | | overall survival (reported) 0.98 [0.60; 1.60] Clinical benefit (assessable) 0.97 [0.88; 1.06] Objective response (assessable) 0.85 [0.72; 1.01] progression-free survival (reported or calculated) 1.00 [0.67; 1.49] Objective response (randomised) 0.85 [0.70; 1.03] Clinical benefit (randomised) 0.96 [0.85; 1.09] | | Rose, 2003 | vs megestrol acetate | | Objective response (assessable) 0.64 [0.45; 0.90] Objective response (randomised) 0.65 [0.45; 0.92] | Clinical benefit (assessable) 0.84 [0.66; 1.08] Clinical benefit (randomised) 0.85 [0.66; 1.10] | | Tominaga, 2003 | vs megestrol acetate | | Objective response (assessable) 0.42 [0.21; 0.81] Objective response (randomised) 0.42 [0.22; 0.82] | Clinical benefit (assessable) 0.69 [0.48; 1.01] Clinical benefit (randomised) 0.70 [0.48; 1.02] |
| Trial | Treatments | Patients | Method |
|---|
| Buzdar, 2001 | (n=-9) vs. (n=-9) | postmenopausal women with advanced breast cancer previously treated with antiestrogens | Sample size: -9/-9 Primary endpoint: FU duration: | | Dombernowsky, 1998 | (n=-9) vs. (n=-9) | patients with locally advanced, locoregionally recurrent or metastatic breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: | | Mourisden, 2001 | (n=-9) vs. (n=-9) | first-line therapy for postmenopausal women with advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: | | Gershanovich, 1998 | (n=-9) vs. (n=-9) | postmenopausal women with advanced breast cancer, previously treated with anti-estrogens | Sample size: -9/-9 Primary endpoint: FU duration: | | Goss, 2007 | (n=-9) vs. (n=-9) | postmenopausal women with advanced receptor-positive breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: | | Rose, 2003 | (n=-9) vs. (n=-9) | second-line endocrine therapy in advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: | | Tominaga, 2003 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
